The wind has long been used as a metaphor for constant change, wayward and capricious. Wind turbine engineers deal with that changeability every day, along with a host of other challenging factors. Their products must operate in desert sandstorms and in corrosive salt water. The ambient temperature at the turbine site can be blisteringly high or numbingly frigid.
Samples are precious resources and integral to the research process. The information derived from them is dependent on their quality, integrity and consistency. And, many samples represent a scientist’s investment in and trust of the biomedical research process. Yet, it is not unusual for samples to go missing, to find that their labels have fallen off or that they have become unusable.
Finding treatments for advanced stage cancer isn’t easy. Therefore, early detection methods are paramount in the fight against the disease. Motivated by the opportunity to intervene as early as possible in the course of cancer, Dr. Muneesh Tewari, a Univ. of Michigan researcher, has been studying the diagnostic potential of blood-based biomarkers.
Gathering all analytical data from different techniques for the same sample isn’t always an easy and routine task. This problem is amplified in high-throughput environments based on sheer volume alone. Review and analysis of information can be time consuming, leading to delays in decision-making that have detrimental effects on productivity and the speed of project completion.
Delivering drugs into the brain to treat neurological diseases and disorders has been a challenge. The current best and easiest way to get drugs anywhere in the body is to take them orally or to administer them intravenously. But the challenges for these routes of drug delivery for targets in the brain are multiple.
A generation ago, wet laboratory space would’ve included fixed casework, dense with laboratory benches, storage cabinets and equipment, but hardly any space or capacity to hold a meeting or accommodate change. Today, laboratory space design reflects an evolution in both the methods of research and the way that scientists work—individually and with their colleagues.
Buzzwords, like a virus, spread inexorably from discipline to discipline. Take “big data,” which originated in supercomputing and now has infected finance, logistics, intelligence and defense and life science. Is there some rule requiring every presentation on genomics to include a slide comparing sequencing costs to Moore’s Law, followed by slides lamenting how much data we are producing and the resources required to act on it?
On the eve of the 25th World AIDS Day (December 2014), President Barack Obama expressed hope to our nation, proclaiming that an “AIDS-free generation is within our reach.” During his speech, Obama expressed how our nation has made significant strides toward strengthening scientific investments, building effective HIV/AIDS education and prevention programs and bringing together public and private stakeholders.
In the U.S. about 12,500 women are diagnosed with cervical cancer a year. Out of these women, about 4,500 progress into invasive cervical cancer or the end stage of the disease. This leaves about 8,000 women a year in the U.S. that are cured through existing standard of care treatment: surgery or chemotherapy/radiation. However, chemotherapy/radiation have terrible side effects in some cases.
Many companies have recognized an untapped opportunity for improving their development process: the requirements traceability matrix. Rather than wait until the end of the development cycle, the team builds the trace matrix when requirements first go under design control, and maintains it all the way through the submission process.
Laboratories are like a living organism: They need to breathe to survive. Air exchange and management is one of a laboratory’s primary functions, and like the creature that breathes with lungs, the research environment contains many cells, or pockets, of both pure and contaminated air. These enclosures protect specimens or samples from the deleterious effects of contaminated air and allow researchers to breathe freely.
In an editorial cartoon that appeared in a recent issue of The Journal of Clinical Investigation, a surgeon wields a scalpel over his patient. The caption reads: “Just a little nip here and there. We don’t want it to look like it’s had any work done.” The catch? The patient is a western blot, and the doctor is presumably making his patient look presentable for publication in a peer-reviewed journal.
The biggest challenges many elite enterprises face are actually external forces completely out of their control, from geopolitical and economic macro trends to global threats to health and the environment. This lack of control creates a tumultuous global business climate that conspires to unravel even the most well-thought-out strategic plans.
Stem cell research has been breaking ground in new application areas over the past few years, and it’s poised for even greater growth as more companies and organizations realize the potential. In the next decade, cell-based therapies will become increasingly common for cancer, immunological disorders, cardiac failure and other conditions.
Progress often requires change. For protein-based diagnostics, multiplexed assays and detection of protein isoforms will drive the adoption of a new strategy for diagnostic testing, called immuno-MS. Enzyme-linked immunosorbent assays (ELISA) have become the standard for antibody-based diagnostic tests in clinical settings. ELISAs provide specific detection of biomarkers through use of antibodies which target specific epitopes on antigens.